DiscovAIR will develop a lung cell atlas. This will be a 3D reconstruction of how the cells in the lungs interact with other cells, certain medications and how the lungs in people with lung diseases are different from those without disease.
The EU provides opportunities and funding for public health and medical research across Europe. We work to ensure that people with lung conditions and the general public have the opportunity to influence research and guidelines at the European level.
One way of achieving this is through participation in EU-funded research projects, in which we advocate for patient involvement, from project design to dissemination.
ELF is primarily interested in pan-European collaboration initiatives, with scope for improving the lives of people with respiratory conditions with tangible outcomes. Our goal in EU projects is twofold:
ELF is motivated to involve patients in all stages of EU projects. Involvement of those with expertise in living with a condition in research study design, on ethics boards and patient input groups can help ensure that recruitment targets are met and that the patients taking part in research can have a positive experience, that real-world outcomes are achieved by the project, appropriate communication and dissemination of the project to key stakeholders outside of the respiratory professional community and a legacy for the project.
BETTER-B is an HORIZON2020 funded study involving international breathlessness experts from respiratory, palliative care and rehabilitative specialisms. The project will test whether an antidepressant can be repurposed to help in managing breathlessness where non-drug treatments cannot be effectively used. ELF is involved in communication and dissemination together with the ERS.
The EU-funded FAIR project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome AMR in pneumonia. The research focuses on the unique immunomodulator flagellin that enhances airway epithelial innate immune defences, and the development of airway-specific aerosol delivery by nebulisation. ELF is involved in communication and dissemination together with the ERS.
UNITE4TB is the newest project of the IMI AMR Accelerator, a public-private collaboration with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections. The 7-year, project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB.
Find out about projects we have worked on in the past that have now ended. Here you can read about what they did and what they learned.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.